Cytotoxic Chemotherapy for Advanced Colorectal Cancer

Size: px
Start display at page:

Download "Cytotoxic Chemotherapy for Advanced Colorectal Cancer"

Transcription

1 Review Article [1] November 02, 2005 By Scott Kopetz, MD [2] and Paulo M. Hoff, MD, FACP [3] Several developments in the past few years have incrementally progressed the field and provided additional insights into the management of advanced colorectal cancer. This review discusses the components of current cytotoxic chemotherapy regimens for advanced colorectal cancer: fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), and oxaliplatin (Eloxatin). The equivalence of several front-line regimens has provided opportunities for increased tailoring of therapies for individual patients. Preliminary data on pharmacogenomics provides hope that we will be able to better match patients with regimens and doses on the basis of individualized predictions of toxicity and response. The importance of second-line therapy in overall survival has again been highlighted; the best outcomes have occurred in patients treated with 5-FU, oxaliplatin, and irinotecan in combination with targeted therapies during the course of their disease. Elderly patients are no exception to this finding. Combination regimens and second-line therapy should be offered to elderly patients who have adequate performance status and no contraindicated comorbid conditions, without regard for their chronological age. Colorectal cancer is the second leading cause of cancer death in the United States. Up to onethird of patients have metastatic disease at the time of initial presentation. Although metastatic colorectal cancer remains a terminal diagnosis for the majority of patients, recent advances have improved outcomes while providing more treatment options for clinicians. The median survival of patients with metastatic disease has gone from 12 to 24 months with increased utilization of combination chemotherapeutic regimens. These new developments have provided opportunities for increased tailoring of therapies to match the characteristics of individual cases and patients. Research presented over the past few years has changed our approach to several important considerations in the treatment of advanced colorectal cancer. Although much attention has been paid to the rapid developments in targeted agents, significant advances have been made in conventional chemotherapy as well. This review discusses these new developments in cytotoxic chemotherapy regimens and describes the changing approach to these treatments, with a separate emphasis on issues in the elderly patient. The addition of targeted agents to these regimens is discussed in an accompanying article by Drs. Marshall and Hwang. Fluorouracil/Leucovorin For many years fluorouracil (5-FU) was the sole chemotherapeutic agent for metastatic colon cancer. Fluorouracil and its metabolites have at least two mechanisms of action: binding thymidylate synthetase, which depletes uracil stores necessary for DNA replication, and incorporation into RNA, which subsequently disrupts protein synthesis. Recent data from the adjuvant setting suggest that below normal levels of thymidylate synthetase, as assessed by immunohistochemical studies, may be associated with prolonged survival.[1] The addition of leucovorin to the regimen improves efficacy by increasing the amount of reduced folate cofactor needed to bind thymidylate synthetase. The addition of leucovorin increased the rate of response to 5-FU from 11% to 21% in metastatic colorectal cancer.[2] Fluorouracil has traditionally been given by bolus infusion in the United States. However, several trials have demonstrated that infusional regimens offer greater benefit, possibly due to more prolonged inhibition of thymidylate synthetase. A meta-analysis of 1,219 patients in six randomized trials of 5-FU administered by bolus or continuous infusion demonstrated a higher response rate in patients who received the drug by continuous infusion (22% vs 14%).[3] The sideeffect profile of continuous infusion therapy included less neutropenia and an increased incidence of hand-foot syndrome.[4] The combination of leucovorin and infusional 5-FU has subsequently been shown to produce better outcomes than the infusional regimen alone.[5] The most commonly used infusional regimens are the German AIO regimen of 5-FU (2,000 to 2,600 mg/m2) over 24 hours with leucovorin (500 mg/ m2) weekly for 6 weeks, followed by 1 or 2 weeks rest, and the de Gramont or LV5FU2 regimen consisting of leucovorin (200 mg/m2 IV over 2 hours) and 5-FU (bolus 400 mg/m2 and infusion 600 mg/m2) on days 1 and 2, repeated every 2 weeks. Page 1 of 9

2 Capecitabine The oral fluoropyrimidine capecitabine (Xeloda) is a prodrug of 5-FU that has activity similar to that of infusional 5-FU. Two large randomized phase III studies demonstrated that capecitabine had a higher response rate (26% vs 17%) and a better safety profile than bolus 5-FU.[6] Side effects are similar to those of infusional 5-FU, although the incidence of handfoot syndrome is higher in patients who receive capecitabine. Thymidine phosphorylase, one of the enzymes responsible for conversion of capecitabine to the active metabolite, is increased in tumor cells, suggesting that the oral prodrug has increased selectivity over infusional 5-FU. Capecitabine is being investigated as a substitute for 5-FU in most frontline regimens. Several recent studies have demonstrated the safety and tolerability of these combinations. Most studies have focused on combinations with oxaliplatin (Eloxatin), five of which were reported at the 2005 American Society of Clinical Oncology Annual Meeting (Table 1). These trials are briefly reviewed here. The CAPOX regimen was compared to FUFOX, a weekly infusional 5-FU plus oxaliplatin regimen.[7] The toxicity profiles were similar, aside Page 2 of 9

3 from a higher incidence of hand-foot syndrome with CAPOX. The response rates for CAPOX and FUFOX were similar (47% vs 49%, P =.70). Although the difference in progressionfree survival did not reach statistical significance (7.0 vs 8.0 months, P =.11), the trend favored the intravenous arm; the difference suggests caution when analyzing this study. The TREE-1 study randomized patients to receive modified FOLFOX6, bfol, or CapeOx.[8] With the approval of bevacizumab (Avastin), enrollment in TREE-1 was discontinued in favor of a similar design with bevacizumab added to each arm (TREE-2). The high rate of diarrhea and dehydration seen with the TREE-1 capecitabine dose of 1,000 mg/m2 twice daily led to a dose reduction in the TREE-2 trial. Bevacizumab added to the efficacy of all regimens, with a clear increase in response rates. The bfol had the lowest response rate, and it was statistically inferior to the response rate seen with the FOLFOX6 regimen. Preliminary results from a third phase III trial of capecitabine/oxaliplatin and infusional 5-FU/oxaliplatin in a slightly different schedule produced comparable toxicity profiles and response rates in the two arms (47% vs 54%, respectively).[9] Interim results were recently presented of another study comparing XELOX to the popular FOLFOX6 regimen after enrollment of 177 of 304 planned patients. This initial safety analysis demonstrated much lower rates of neutropenia in patients who received the XELOX regimen than in those who received FOLFOX6 at an oxaliplatin dose of 100 mg/m2.[10] A strategy of prolonged continuous infusion 5-FU with oxaliplatin was compared to XELOX in a randomized phase II study.[11] Survival data are still maturing, but preliminary results demonstrate similar response rates. Surgical resection of liver metastases was attempted more frequently in the XELOX arm (9.6% vs 4.1%). A report has been recently published of a more dose-intense capecitabine regimen in 89 patients.[12] In this study, capecitabine doses of 3,500 mg/m2 were given on days 1-7 and 14-21, with oxaliplatin at 85 mg/m2 days 1 and 14, repeated every 4 weeks. Response rates were higher than those of the standard XELOX regimen (55% vs 42%), and toxicity profiles were similar. Median progression-free survival also favored the dose-intense regimen (10.5 vs 6.0 months, P <.01). Although capecitabine's potential as a substitute for infusional 5-FU was confirmed in these studies, larger phase III studies are needed to demonstrate equivalence to FOLFOX. A trial comparing FOLFOX plus bevacizumab to XELOX plus bevacizumab is ongoing and will address the interchangeability of capecitabine for 5-FU. Until these data are presented, combination capecitabine regimens should be reserved for patients understanding and willing to accept that there is a small potential risk of a difference in efficacy, for the convenience of an oral fluoropyrimidine. The principle of combining capecitabine with irinotecan (Camptosar) was proven by the combination's effectiveness in phase II studies. However, recent larger series combining capecitabine and irinotecan have been less successful. A large European Organisation for Research and Treatment of Cancer trial compared CAPE/IRI (capecitabine at 1,000 mg/m2 twice a day for days 1-14 and irinotecan at 250 mg/m2 day 1, on a 3-week cycle) to FOLFIRI (leucovorin at 200 mg/m2 day 1, 5-FU at 400 mg/m2 bolus, days 1 and 2, 600-mg infusion over 22 hours, days 1 and 2; irinotecan at 180 mg/m2 on day 1, on a 2-week cycle).[13] The trial was stopped early owing to increased mortality in the CAPE/ IRI arm (6 deaths in 44 patients). The deaths were the result of severe diarrhea or thromboembolic events. Dose reduction was required in 61% of patients on the CAPE/IRI arm. Patients also were randomized to receive celecoxib (Celebrex) or placebo, although this did not have an apparent impact on the toxicity. These poor results were similar to those of a smaller phase II trial of the same regimen.[14] In that small study, dose reductions were required in 80% of the patients owing to diarrhea and neutropenia. Further studies of this combination are planned with a reduced dose of irinotecan. An alternate regimen employs a 2-week cycle of irinotecan at 175 mg/m2 on day 1 and capecitabine at 1,000 mg/m2 bid days 2-8, with upfront dose reductions to 140 mg/m2 and 750 mg/m2 bid, respectively, for patients older than 65.[15] The overall response rate was 50%. Grade 3 or 4 diarrhea or neutropenia occurred in less than 2% of cycles. This approach may be an alternative to the earlier, more toxic, regimens. Irinotecan Irinotecan has been used successfully as a single agent and in combination regimens. Irinotecan is a prodrug that is metabolized in the liver by uridine diphosphate glucuronosyl transferases (UGT) into SN-38, an active topoisomerase inhibitor. The toxicity profile is notable for significant diarrhea, which can be fatal in severe cases. Combination of irinotecan with bolus 5-FU and leucovorin in the IFL regimen resulted in high rates of toxicity. In the initial trial of IFL, grade 3 or 4 diarrhea occurred in 23% of patients.[16] Efficacy was increased; the combination yielded a response rate of 39% and a median progression-free survival of 7.0 months. Several alternative combinations have been investigated in attempts to improve response rates and decrease toxicity. The AIO infusional 5-FU regimen was combined with irinotecan, yielding a response rate of 62% and time to progression of 8.5 months.[17] However, the rate of grade 3 or 4 diarrhea remained high, at 36%. The FOLFIRI regimen had a similar response rate (56%) and median progression- free survival Page 3 of 9

4 (11 months) but an improved toxicity profile; the rate of grade 3 or 4 diarrhea was only 14%.[18] Given its high response rate and tolerability, this regimen is a reasonable first-line therapy for metastatic colorectal cancer. Several recent studies have investigated the importance of UGT promoter polymorphisms in predicting irinotecan-induced toxicity and response to therapy. In one study of a group of 81 patients receiving frontline irinotecan-containing regimens, dose-limiting toxic effects occurred in 18% of patients with mutations in UGT1A1.[19] In contrast, none of those without the mutation discontinued the treatment because of toxicity. Response rates were lower in patients with the mutation (57% vs 43%). A similar study of 67 patients receiving irinotecan with capecitabine demonstrated that those with mutations in UGT1A7 had a higher response rate and lower toxicity rate than patients with a wild-type genotype.[ 20] The response rate was 85% (11 of 13 patients) in patients with mutations associated with lower UGT1A7 activity and 44% (19 of 43) in patients with other genotypes. Similarly, none of the patients with these mutations had grade 3 or 4 diarrhea or neutropenia, whereas 23% of patients with other genotypes experienced at least one of these toxic effects. Oxaliplatin As a single agent, oxaliplatin has minimal efficacy in metastatic colorectal cancer. In combination with 5-FU/leucovorin, however, oxaliplatin has significant synergy and yields high response rates. The most common oxaliplatin-containing combination regimen, FOLFOX, has undergone several iterations. The FOLFOX4 regimen uses bolus and continuous infusion 5-FU on days 1 and 2 with oxaliplatin at 85 mg/m2. This regimen has been shown to be superior to irinotecan with bolus 5-FU/leucovorin (IFL) in a large trial of 795 patients, which included a comparison of IFL to FOLFOX4 and found a higher response rate and overall survival duration with FOLFOX4 (45% vs 31%, 19.5 vs 15.0 months, respectively).[ 21] Although FOLFOX4 was better tolerated than IFL, 20% of the patients who received FOLFOX4 developed grade 3 neuropathy. FOLFOX6 increased the dose of oxaliplatin to 100 mg/m2 and attempted to improve patient convenience by removing the 5-FU bolus on the second day. This resulted in an increased rate of neuropathy, however, and the oxaliplatin dose was reduced back to 85 mg/m2 in the popular modified FOLFOX6 regimen. In frontline therapy, this regimen produced a response rate of 54% and a median progression-free survival duration of 8.0 months[18]; it is now the most widely used regimen in the United States. The neuropathy associated with oxaliplatin is usually dose-dependent; most patients experience dose-limiting neuropathy after a cumulative dose of 700 to 800 mg/m2 (8 to 10 cycles). There is a subset of patients who develop early-onset neuropathy. Recent data suggest that a glutathione S-transferase polymorphism may predict this early toxicity.[22] The 13% of patients with the GSTP1 I105V polymorphism were more likely to stop treatment because of neuropathy (23% vs 10%) and had a higher rate of early-onset neuropathy. These results await further validation before this approach can move into the clinic. The combination of irinotecan and oxaliplatin (IROX) has been investigated in the front-line setting in several studies, with disappointing results. When compared to FOLFOX4, IROX had a trend for lower response rate and shorter overall survival interval.[21] A similar combination was recently compared to FOLFIRI, revealing a trend toward worse progression-free survival for IROX (8.7 vs 7.3 months, P =.15).[23] Toxicity rates also were higher in the IROX arm. This combination does not appear to improve the results seen with FOLFOX or FOLFIRI and should not be used routinely in front-line therapy. Selecting a Combination Modified FOLFOX6 and FOLFIRI have shown similar efficacy and tolerability. The different side-effect profiles allow tailoring of front-line regimens to individual patients. Patients with preexisting neuropathies or underlying conditions that put them at risk for early neuropathy from oxaliplatin, such as poorly controlled diabetes, could receive FOLFIRI. Similarly, patients with symptoms of irritable bowel syndrome or poor tolerance of diarrhea may better tolerate modified FOLFOX6. It is our hope that pharmacogenomic studies, once validated, may help guide the selection and dosing of an appropriate regimen for each individual. The question of which combination regimen to use in the front-line setting was addressed by a trial that randomized patients to receive frontline FOLFOX6 or FOLFIRI, followed by planned treatment with the alternate regimen on disease progression.[ 18] Front-line response rates, progression-free survival, and overall survival were similar between the two arms. Several limitations of this study complicate interpretation, including lower rates of second-line therapy per protocol in the front-line FOLFIRI arm and a mismatch in the rates of subsequent metastasectomy in the two groups. Nevertheless, this long overall survival duration demonstrates the importance of treatment with an active second-line agent in combination with 5-FU/leucovorin. The most important determinant of overall survival duration appears to be the number of active agents that a patient receives. A retrospective study of seven phase III trials demonstrated that overall survival duration was greatest in patients who had received 5-FU/leucovorin, irinotecan, and oxaliplatin during the course of their treatment[24] (Figure 1). A large study from the United Kingdom, MRC-FOCUS, evaluated the appropriate sequence of Page 4 of 9

5 chemotherapy.[ 25] The trial has only been presented in preliminary form and full results are not available.up-front combination therapy, when compared to infusional 5-FU followed by the addition of irinotecan or oxaliplatin on disease progression, did not show a significant difference in overall survival, despite a higher response rate in patients who initially received combination regimens. However, the median survivals for all arms were shorter than expected, and the relatively small number of patients receiving all three active agents may have played a significant role in these results. Elderly Patients Although the tendency is to view elderly patients as being less tolerant of chemotherapy, data suggest that elderly patients tolerate chemotherapy well and enjoy the same benefit from therapy as younger patients. A meta-analysis of adjuvant chemotherapy for elderly patients from 2001 demonstrated that there was no significant difference in durations of overall survival or recurrence-free survival between elderly patients and younger patients.[26] The same has been shown for elderly patients treated in Europe with 5-FU-containing regimens for metastatic colorectal cancer. Response rates and overall survival were the same for patients aged < 70 years and those aged 70 years.[27] The number of patients with poor performance status and tumorrelated symptoms was the same in each group. A recent population-based retrospective analysis from Canada demonstrated that elderly patients ( 70 years) were less likely than younger patients to receive chemotherapy for advanced colorectal cancer (43% vs 70% of patients < 70 years).[28] When given, treatment was more likely to be single-agent 5-FU or capecitabine. Survival duration for elderly patients treated with doublet therapy was the same as that for younger patients. Most of the difference seen in overall survival duration between the two age groups was the result of the higher utilization of combination therapy in the younger group. These results suggest that elderly patients should not be denied combination therapy because of concerns about decreased efficacy (Table 2). Several recent reports have evaluated the role of capecitabine in treatment of the elderly patient. A strategy of dose escalation with the XELOX regimen was studied in an elderly population (median age: 75 years; range: years) to evaluate toxicity and efficacy.[29] The oxaliplatin dose was started at 85 mg/m2 and escalated in subsequent cycles up to 130 mg/m2 as tolerated. Forty-six percent of patients reached the full dose. With this regimen, 5% developed grade 3 or 4 hematologic toxicity, and severe hand-foot syndrome occurred in 13%. Only 8% of patients developed grade 3 peripheral neuropathy. Efficacy was close to that in younger populations at 41%, with a median progressionfree survival Page 5 of 9

6 duration of 27 weeks. These results suggest that the XELOX regimen is well tolerated in the "fit" elderly patient. It is unclear, however, how aggressively the dose was escalated and whether more patients would have tolerated the traditional oxaliplatin starting dose of 130 mg/m2. A smaller study of XELOX with oxaliplatin at 130 mg/m2 in elderly patients ( 70 years) demonstrated that the traditional combination was well tolerated.[30] In this study of 50 patients, the median relative dose intensity was maintained above 90% for both capecitabine and oxaliplatin. A subgroup analysis of elderly patients ( 65 years) in a separate phase II trial of XELOX demonstrated that response rates, median progression-free survival, and overall survival were similar to those in younger patients.[ 31] Toxicity, dose reductions, and withdrawals due to toxicity were comparable in both age groups, suggesting that the higher starting dose is tolerated in the elderly population. Another approach to dose reduction in the elderly, the bifractionated oxaliplatin regimen, was recently reported for front-line treatment of metastatic colorectal cancer.[32] In elderly patients ( 70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better, a 2-day regimen of daily oxaliplatin (45 mg/m2) and bolus plus continuous infusion 5-FU was given every 2 weeks. A total of 78 patients were treated, and rates of grade 3 or 4 diarrhea, mucositis, and neuropathy were low. The rate of grade 3 or 4 neutropenia, known to be higher in elderly patients, was 32%. The response rate was 51%, similar to that of traditional FOLFOX regimens. Importantly, almost half of these patients were able to receive secondline therapy, which was likely responsible for the impressive 20.1-month overall survival duration seen in this elderly population. However, the need for this dose-reduced regimen is unclear, as the fit elderly patient enrolled in these clinical trials appears to tolerate the traditionally dosed regimens well and obtains the same clinical benefit as the younger patient. For those elderly patients unable to tolerate standard combination regimens owing to poor performance status or limiting comorbid conditions, one recently presented trial addressed the role of single-agent capecitabine in front-line management. A multicenter phase I/II trial evaluated the use of low-dose capecitabine (1,000 mg/m2 twice daily) primarily in patients who were elderly ( 65 years), had a poor performance status (ECOG 1 or 2), or had elevated levels of liver enzymes.[33] Grade 3 or 4 toxicities occurred in 23% of the patients, mostly hand-foot syndrome Page 6 of 9

7 (8%) and diarrhea (7%). The response rate was low at 19%, with a median progression- free survival of 5.3 months. A subgroup of elderly patients with an ECOG performance status of 0 had a median overall survival of 19.7 months. This reflects the heterogeneous study population and the fact that the broad inclusion criteria likely included elderly patients who would have tolerated combination regimens. Evidence suggests that elderly patients with a good performance status and minimal comorbid conditions are able to tolerate standard dose combination chemotherapy and derive as much benefit from it as their younger counterparts. For patients with poor performance status or multiple comorbid conditions, treatment with singleagent capecitabine or infusional 5-FU is appropriate. Overall survival duration in both of these groups appears to be dependent on the patient's ability to tolerate a second-line regimen. Conclusions Several advances in the treatment of metastatic colorectal cancer were recently presented, providing further insight into the optimal regimens for maximizing response and minimizing toxicity. Interest in substituting capecitabine for infusional 5-FU has led to several studies with encouraging early results, although final results will be needed before this can be recommended routinely. Both FOLFOX and FOLFIRI are acceptable front-line regimens, and the choice of front line is less important than the availability of all active drugs in some rational sequence. The potential for pharmacogenomic-based therapy is seen in several exploratory studies. Recent studies demonstrate that elderly patients can be treated with the same combination therapies as younger patients with similar tolerability and efficacy. Although these results and the addition of targeted agents continue to incrementally prolong patient survival, the goal of increasing the rate of cure of metastatic colorectal cancer is still elusive. Disclosures: Dr. Hoff has received research grants from Roche, Sanofi, Pfizer, and Genentech. References: 1. Johnston PG, Benson A, Catalano P, et al: The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis (abstract 3510). J Clin Oncol 23(suppl 16S):248s, Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 22: , Meta Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: , Meta Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16: , Schmoll HJ, Köhne CH, Lorenz M, et al: Weekly 24h infusion of high-dose 5-fluorouracil (5-FU24h) with or without folinic acid vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer: A randomized phase III study of the EORTC GITCCG and the AIO (abstract 935). J Clin Oncol 19:241a, Van Cutsem E, Hoff PM, Harper P, et al: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90: , Arkenau H, Schmoll H, Kubicka S, et al: Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis (abstract 3507). J Clin Oncol 23(suppl 16S):247s, Hochster HS, Welles L, Hart L, et al: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 & 2 studies (abstract 3515). J Clin Oncol 23(suppl 16S):249s, Sastre J, Massuti B, Tabernero JM, et al: Preliminary results of a randomized phase III trial of the TTD group comparing capecitabine and oxaliplatin (CapeOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC) (abstract 3524). J Clin Oncol 23(suppl 16S):252s, Ducreux M, Adenis A, Bennouna J, et al: Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. Infusional 5-fu/lv plus oxaliplatin (FOLFOX- 6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis (abstract 3596). J Clin Oncol 23(suppl 16S):270s, Martoni A, Pinto C, Di Fabio F, et al: Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first line treatment in Page 7 of 9

8 advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA study (abstract 3617). J Clin Oncol 23(suppl 16S):275s, Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: , Kohne C-H, de Greve J, Bokemeyer C, et al: Capecitabine plus irinotecan versus 5-FU/ FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study (abstract 3525). J Clin Oncol 23(suppl 16S):252s, Cartwright T, Lopez T, Vukelja SJ, et al: Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5:50-56, Garcia-Alfonso P, Perez-Manga G, Gonzalez MC, et al: A phase II trial of a biweekly schedule of capecitabine plus irinotecan (I) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC) (abstract 3540). J Clin Oncol 23(suppl 16S):256s, Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343: , Kohne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: EORTC Gastrointestinal Group Study J Clin Oncol 23: , Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: , Schulz C, Schalhorn A, Schwabe W, et al: Impact of gene promoter polymorphism of the UGT1A1-gene on the occurrence of irinotecan-induced side effects and drug efficacy (abstract 3570). J Clin Oncol 23(suppl 16S):263s, Carlini LE, Meropol NJ, Bever J, et al: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: , Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, Grothey A, McLeod HL, Green EM, et al: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity (abstract 3509). J Clin Oncol 23(suppl 16S):248s, Schalhorn A, Ludwig FW, Quietzsch D, et al: Phase III trial of irinotecan plus oxalipatin (IROX) versus irinotecan plus 5- FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-trial (abstract 3516). J Clin Oncol 23(suppl 16S):250s, Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: , Seymour MT: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135-patient randomized trial in advanced colorectal cancer (abstract 3518). J Clin Oncol 23(suppl 16S):250s, Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: , Folprecht G, Cunningham D, Ross P, et al: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 15: , Ho C, O Reilly S, Ng K, et al: Population- based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes (abstract 3614). J Clin Oncol 23(suppl 16S):274s, Comella P, Natale D, Farris A, et al: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group trial Cancer 104: , Salud A, Escudero P, Feliú J, et al: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (abstract 3620). J Clin Oncol 23(suppl 16S):276s, Twelves CJ, Butts CA, Cassidy J, et al: Capecitabine/oxaliplatin, a safe and active firstline regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Page 8 of 9

9 Colorectal Cancer 5: , Massacesi C, Lippe P, Recchia F, et al: Bi-fractionated oxaliplatin (L-OHP) plus 5fluorouracil/leucovorin for elderly patients with advanced colorectal cancer (CRC) (abstract 3619). J Clin Oncol 23(suppl 16S):275s, Cripps MC, Vincent M, Jonker D, et al: Dose reduced first-line capecitabine (Xeloda) monotherapy in older and less fit patients with advanced colorectal cancer (ACRC) (abstract 3577). J Clin Oncol 23(suppl 16S):265s, Source URL: ncer Links: [1] [2] [3] Page 9 of 9

Management of Advanced Colorectal Cancer in Older Patients

Management of Advanced Colorectal Cancer in Older Patients Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate

More information

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Update on Chemotherapy for Advanced Colorectal Cancer

Update on Chemotherapy for Advanced Colorectal Cancer Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have

More information

Integrating Oxaliplatin into the Management of Colorectal Cancer

Integrating Oxaliplatin into the Management of Colorectal Cancer Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

Therapy for Metastatic Colorectal Cancer

Therapy for Metastatic Colorectal Cancer Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key

More information

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical

More information

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools - Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -

More information

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal

More information

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W 癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Chemotherapy options and outcomes in older adult patients with colorectal cancer

Chemotherapy options and outcomes in older adult patients with colorectal cancer Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School

More information

Original article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.

Original article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P. Original article Annals of Oncology 15: 1013 1017, 2004 DOI: 10.1093/annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients

More information

Adjuvant treatment Colon Cancer

Adjuvant treatment Colon Cancer ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information

Current Status of Adjuvant Therapy for Colorectal Cancer

Current Status of Adjuvant Therapy for Colorectal Cancer Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas

More information

RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER

RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS

More information

clinical practice guidelines

clinical practice guidelines Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes

More information

Does it matter which chemotherapy regimen you partner with the biologic agents?

Does it matter which chemotherapy regimen you partner with the biologic agents? Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential

More information

療指引 34 Adjuvant Therapy of Colon Cancer

療指引 34 Adjuvant Therapy of Colon Cancer 療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine

More information

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:

More information

OVERALL CLINICAL BENEFIT

OVERALL CLINICAL BENEFIT cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence

More information

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience 226 research article Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience Janja Ocvirk 1,2, Maja Ebert Moltara 1,Tanja Mesti

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

More information

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution

More information

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,

More information

trial update clinical

trial update clinical clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must

More information

Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook. doi: /theoncologist

Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook. doi: /theoncologist Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook The Oncologist 2005, 10:250-261. doi: 10.1634/theoncologist.10-4-250 The online version of this article, along with

More information

Comparison of first-line bevacizumab in combination with mfolfox6 or XELOX in metastatic colorectal cancer

Comparison of first-line bevacizumab in combination with mfolfox6 or XELOX in metastatic colorectal cancer JBUON 2015; 20(2): 460-467 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Comparison of first-line bevacizumab in combination with mfolfox6 or

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*

The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting* Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different

More information

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients

More information

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Bevacizumab is currently licensed for the following indication relevant for this NICE review: Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both

More information

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools - Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis

More information

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of

More information

ORIGINAL ARTICLE. M. Bakogeorgos, G. Mountzios, G. Kotsantis, P. Economopoulou, N. Fytrakis, N. Kentepozidis. Summary.

ORIGINAL ARTICLE. M. Bakogeorgos, G. Mountzios, G. Kotsantis, P. Economopoulou, N. Fytrakis, N. Kentepozidis. Summary. JBUON 2013; 18(3): 629-634 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly

More information

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014

More information

Original article. Introduction

Original article. Introduction Original article Annals of Oncology 13: 716 720, 2002 DOI: 10.1093/annonc/mdf091 Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the

More information

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000

More information

A Single-Center Phase 2 Trial. Bevacizumab is a humanized immunoglobulin G1 murine antibody directed against all isoforms of

A Single-Center Phase 2 Trial. Bevacizumab is a humanized immunoglobulin G1 murine antibody directed against all isoforms of Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer A Single-Center Phase 2 Trial Bruno Vincenzi,

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m

More information

Adjuvant therapy in colon cancer: which treatment in 2005?

Adjuvant therapy in colon cancer: which treatment in 2005? Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of

More information

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1 Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated

More information

DALLA CAPECITABINA AL TAS 102

DALLA CAPECITABINA AL TAS 102 DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu

More information

Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER?

Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER? Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER? Version 11/24/2011 3:08 PM Q11 TABLE OF CONTENTS SCIENTIFIC REPORT... 6 1 INTRODUCTION... 6 1.1 PICO...

More information

Adjuvant/neoadjuvant systemic treatment of colorectal cancer

Adjuvant/neoadjuvant systemic treatment of colorectal cancer 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico

More information

OWa 22 80) :IEZ

OWa 22 80) :IEZ Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab

More information

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日 大腸直腸癌 抗癌藥物治療指 討論日期 團隊討論 : 05 年 0 月 9 日 三院討論 : 05 年 2 月 7 日 團隊確認 : 06 年 月 25 日 核備日期 : 06 年 4 月 8 日 Adjuvant Therapy of Colon Cancer mfolfox6 參考文獻 -3 Oxaliplatin 85 Q2W 2 Leucovorin 400 Q2W 2 5-FU 400 Q2W

More information

Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations

Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations D Papamichael MB BS FRCP On behalf of the SIOG CRC in the Elderly Task Force Madrid 10/11/07 8 th Meeting of the International

More information

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,

More information

Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer

Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer Kanwal Raghav, MD, and Cathy Eng, MD Abstract The existing therapeutic armamentarium for first-line treatment of metastatic

More information

Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR PATIENTS TREATED WITH IRINOTECAN Policy Number 2.02.

Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR PATIENTS TREATED WITH IRINOTECAN Policy Number 2.02. Page: 1 of 5 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR Policy Number 2.02.34 Category Laboratory Tests Effective Date

More information

NICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery

NICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery NICE Health Technology Re-appraisal The use of irinotecan, oxaliplatin and raltitrexed in the treatment of advanced colorectal cancer (review of guidance No. 33) Submission of the British Association of

More information

Academia Pharma Intersect: Key Words. Bevacizumab FOLFOX protocol FOLFIRI protocol Safety Treatment outcome

Academia Pharma Intersect: Key Words. Bevacizumab FOLFOX protocol FOLFIRI protocol Safety Treatment outcome The Oncologist Academia Pharma Intersect: Gastrointestinal Cancer Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX Bevacizumab or FOLFIRI

More information

(5-fluorouracil 5-FU) [ ] FOLFOXIRI FOLFOXIRI. [DOI] /j.issn

(5-fluorouracil 5-FU) [ ] FOLFOXIRI FOLFOXIRI. [DOI] /j.issn 248 2016 3 1 41 3 FOLFOXIRI 21 [ ] FOLFOXIRI 21 FOLFOXIRI 150mg/m 2 d 1 85mg/m 2 d 1 200mg/m 2 d 1 5-2800mg/m 2 48h 2 1 3 4 42.9%(9/21) 8 (38.1%) 1 (4.8%)3 4.8%(1 ) 4 98.5% 93.4% 5-97.6% 14 (66.7%) 6 (28.6%)

More information

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective

More information

Targeted therapies in colorectal cancer: the dos, don ts, and future directions

Targeted therapies in colorectal cancer: the dos, don ts, and future directions Editorial Targeted therapies in colorectal cancer: the dos, don ts, and future directions Marwan Fakih City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA 91010, USA Corresponding to:

More information

Key Words. Biologic therapy Chemotherapy Colorectal cancer Metastatic

Key Words. Biologic therapy Chemotherapy Colorectal cancer Metastatic The Oncologist Gastrointestinal Cancer Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials BERT H. O NEIL,RICHARD M. GOLDBERG Division of Hematology and Oncology,

More information

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev

More information

Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer -

Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie

More information

Overview. Author Summary: Abstract and Brief Discussion

Overview. Author Summary: Abstract and Brief Discussion Overview First Published Online October 3, 2014 DOI: 10.1634/theoncologist.2014-0159 Title: A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic

More information

What s New? Dr. Barbara Melosky

What s New? Dr. Barbara Melosky Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment

More information

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running

More information

First line treatment in metastatic colorectal cancer

First line treatment in metastatic colorectal cancer First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was

More information

Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms

Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms 21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik

More information

Chemotherapy re-challenge response rate in metastatic colorectal cancer

Chemotherapy re-challenge response rate in metastatic colorectal cancer Original Article Chemotherapy re-challenge response rate in metastatic colorectal cancer Alexandra E. Chambers 1, Jacob Frick 1, Natalee Tanner 1, Richard Gerkin 2, Madappa Kundranda 3, Tomislav Dragovich

More information

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients

Association of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered

More information

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of

More information

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Original article Annals of Oncology 15: 1330 1338, 2004 doi:10.1093/annonc/mdh344 Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis

More information

Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran,

Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran, 2016 jpc.tums.ac.ir Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran, 2008-2014 Ebrahim Salehifar 1*, Shayeste Gheibi 2, Ghasem Janbabaei

More information

Opinion 17 October 2012

Opinion 17 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 October 2012 VECTIBIX 20 mg/ml, concentrate for solution for infusion B/1 vial of 5 ml (CIP code: 3400957181857)

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

The ESMO consensus conference on metastatic colorectal cancer

The ESMO consensus conference on metastatic colorectal cancer ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working

More information

ADVANCES IN COLON CANCER

ADVANCES IN COLON CANCER ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI

More information

CHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012

CHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012 CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of

More information

Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early

More information

Key words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin.

Key words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin. Original Article 297 Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase II Study Jen-Seng Huang, MD; Cho-Li

More information

Has Real Progress Been Made in Chemotherapy for Colon Cancer?

Has Real Progress Been Made in Chemotherapy for Colon Cancer? Series Editor: Melvin Schapiro, M.D. Has Real Progress Been Made in Chemotherapy for Colon Cancer? Avrum Z. Bluming The introduction of capecitabine, irinotecan, oxaliplatin, and the anti-angiogenesis

More information

INTRODUCTION. Jpn J Clin Oncol 2005;35(9) doi: /jjco/hyi140. Gil Medical Center, Incheon, Korea

INTRODUCTION. Jpn J Clin Oncol 2005;35(9) doi: /jjco/hyi140. Gil Medical Center, Incheon, Korea Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience

More information

RESEARCH ARTICLE. Joanne Chiu 1, Vikki Tang 1, Roland Leung 1, Hilda Wong 1, Kin Wah Chu 2, Jensen Poon 3, Richard J Epstein 4, Thomas Yau 1,3,5 *

RESEARCH ARTICLE. Joanne Chiu 1, Vikki Tang 1, Roland Leung 1, Hilda Wong 1, Kin Wah Chu 2, Jensen Poon 3, Richard J Epstein 4, Thomas Yau 1,3,5 * DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6585 Adjuvant XELOX in Asian Patients with Colorectal Cancer RESEARCH ARTICLE Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin

More information

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,

More information

ANTICANCER RESEARCH 26: (2006)

ANTICANCER RESEARCH 26: (2006) Clinical Impact of Adjuvant Chemotherapy on Patients with Stage III Colorectal Cancer: l-lv/5fu Chemotherapy as a Modified RPMI Regimen is an Independent Prognostic Factor for Survival TSUKASA HOTTA, KATSUNARI

More information

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases

Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad

More information

CLINICAL INVESTIGATION

CLINICAL INVESTIGATION Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal

More information

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif

More information

Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer

Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer ONCOLOGY LETTERS 13: 4947-4952, 2017 Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer TARO FUKUI, KOICHI SUZUKI, KOSUKE

More information

Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer

Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer 794 Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer MINA IWAI 1, MICHIO KIMURA 1, EISEKI USAMI 1, TOMOAKI YOSHIMURA 1 and HITOMI TERAMACHI 2 1 Department of Pharmacy,

More information

Curative treatment strategies for colorectal

Curative treatment strategies for colorectal EVALUATING DRUGS FOR COLORECTAL CANCER: RECENT CLINICAL TRIALS Robert J. Ignoffo, PharmD ABSTRACT Until the late 1990s, fluorouracil (FU) plus leucovorin (LV) was the standard adjuvant therapy for stage

More information

Incorporating biologics in the management of older patients with metastatic colorectal cancer

Incorporating biologics in the management of older patients with metastatic colorectal cancer Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014

More information

Radiation Therapy for Resectable Colon Cancer

Radiation Therapy for Resectable Colon Cancer Review Article [1] February 01, 2006 By Brian G. Czito, MD [2], Johanna C. Bendell, MD [3], and Christopher G. Willett, MD [4] Colon cancer is a major public health problem. The primary treatment is resection.

More information

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate

More information

Author's response to reviews

Author's response to reviews Author's response to reviews Title: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II

More information

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta242

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta242 Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first- line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination

More information